Matches in SemOpenAlex for { <https://semopenalex.org/work/W3076329354> ?p ?o ?g. }
- W3076329354 endingPage "1298" @default.
- W3076329354 startingPage "1287" @default.
- W3076329354 abstract "C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components. Previous studies showed that treatment with corticosteroids plus mycophenolate mofetil (MMF) was associated with improved outcomes, although the genetic profile of these patients was not systematically analyzed. This study aims to analyze the main determinants of disease progression and response to this therapeutic regimen.We conducted a retrospective, multicenter, observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients diagnosed with C3 glomerulopathy (n=81) or dense deposit disease (n=16) between January 1995 and March 2018 were enrolled. Multivariable and propensity score matching analyses were used to evaluate the association of clinical and genetic factors with response to treatment with corticosteroids and MMF as measured by proportion of patients with disease remission and kidney survival (status free of kidney failure).The study group comprised 97 patients (84% C3 glomerulopathy, 16% dense deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this treatment was associated with a higher rate of remission and lower probability of kidney failure (79% and 14%, respectively) compared with patients treated with other immunosuppressives (24% and 59%, respectively), or ecluzimab (33% and 67%, respectively), or conservative management (18% and 65%, respectively). The therapeutic superiority of corticosteroids plus MMF was observed both in patients with complement abnormalities and with autoantibodies. However, patients with pathogenic variants in complement genes only achieved partial remission, whereas complete remissions were common among patients with autoantibody-mediated forms. The main determinant of no remission was baseline proteinuria. Relapses occurred after treatment discontinuation in 33% of the patients who had achieved remission with corticosteroids plus MMF, and a longer treatment length of MMF was associated with a lower risk of relapse.The beneficial response to corticosteroids plus MMF treatment in C3 glomerulopathy appears independent of the pathogenic drivers analyzed in this study." @default.
- W3076329354 created "2020-08-24" @default.
- W3076329354 creator A5001450021 @default.
- W3076329354 creator A5003429051 @default.
- W3076329354 creator A5004108111 @default.
- W3076329354 creator A5005524206 @default.
- W3076329354 creator A5007064707 @default.
- W3076329354 creator A5010010165 @default.
- W3076329354 creator A5010267392 @default.
- W3076329354 creator A5015196046 @default.
- W3076329354 creator A5017174323 @default.
- W3076329354 creator A5019038656 @default.
- W3076329354 creator A5019128316 @default.
- W3076329354 creator A5019202081 @default.
- W3076329354 creator A5023919138 @default.
- W3076329354 creator A5024530998 @default.
- W3076329354 creator A5024926926 @default.
- W3076329354 creator A5025647390 @default.
- W3076329354 creator A5025686184 @default.
- W3076329354 creator A5031271393 @default.
- W3076329354 creator A5032703651 @default.
- W3076329354 creator A5037244809 @default.
- W3076329354 creator A5040961802 @default.
- W3076329354 creator A5042551332 @default.
- W3076329354 creator A5045230922 @default.
- W3076329354 creator A5046852623 @default.
- W3076329354 creator A5048784225 @default.
- W3076329354 creator A5050443490 @default.
- W3076329354 creator A5052017202 @default.
- W3076329354 creator A5052276722 @default.
- W3076329354 creator A5056059126 @default.
- W3076329354 creator A5061775674 @default.
- W3076329354 creator A5063908674 @default.
- W3076329354 creator A5065674517 @default.
- W3076329354 creator A5066488894 @default.
- W3076329354 creator A5066933824 @default.
- W3076329354 creator A5068648020 @default.
- W3076329354 creator A5070761001 @default.
- W3076329354 creator A5070978722 @default.
- W3076329354 creator A5071197775 @default.
- W3076329354 creator A5071898717 @default.
- W3076329354 creator A5077303642 @default.
- W3076329354 creator A5080788963 @default.
- W3076329354 creator A5081619092 @default.
- W3076329354 creator A5083034201 @default.
- W3076329354 creator A5086995662 @default.
- W3076329354 date "2020-08-19" @default.
- W3076329354 modified "2023-10-18" @default.
- W3076329354 title "Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease" @default.
- W3076329354 cites W1602285939 @default.
- W3076329354 cites W1967188173 @default.
- W3076329354 cites W1969801543 @default.
- W3076329354 cites W1981786843 @default.
- W3076329354 cites W1996592638 @default.
- W3076329354 cites W2035255371 @default.
- W3076329354 cites W2035304079 @default.
- W3076329354 cites W2045957103 @default.
- W3076329354 cites W2051485743 @default.
- W3076329354 cites W2061904336 @default.
- W3076329354 cites W2074855979 @default.
- W3076329354 cites W2077144266 @default.
- W3076329354 cites W2077994995 @default.
- W3076329354 cites W2107516496 @default.
- W3076329354 cites W2137697380 @default.
- W3076329354 cites W2138581004 @default.
- W3076329354 cites W2157239580 @default.
- W3076329354 cites W2157892794 @default.
- W3076329354 cites W2284643917 @default.
- W3076329354 cites W2554519074 @default.
- W3076329354 cites W2734621863 @default.
- W3076329354 cites W2753421317 @default.
- W3076329354 cites W2761873674 @default.
- W3076329354 cites W2775288206 @default.
- W3076329354 cites W2781580267 @default.
- W3076329354 cites W2783084540 @default.
- W3076329354 cites W2786188147 @default.
- W3076329354 cites W2792370024 @default.
- W3076329354 cites W2800809683 @default.
- W3076329354 cites W2887346611 @default.
- W3076329354 cites W2888224013 @default.
- W3076329354 cites W2897977370 @default.
- W3076329354 cites W2914604561 @default.
- W3076329354 cites W2928285267 @default.
- W3076329354 cites W2941771253 @default.
- W3076329354 cites W2998859761 @default.
- W3076329354 cites W954655434 @default.
- W3076329354 cites W2791803627 @default.
- W3076329354 doi "https://doi.org/10.2215/cjn.15241219" @default.
- W3076329354 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7480558" @default.
- W3076329354 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32816888" @default.
- W3076329354 hasPublicationYear "2020" @default.
- W3076329354 type Work @default.
- W3076329354 sameAs 3076329354 @default.
- W3076329354 citedByCount "27" @default.
- W3076329354 countsByYear W30763293542020 @default.
- W3076329354 countsByYear W30763293542021 @default.
- W3076329354 countsByYear W30763293542022 @default.
- W3076329354 countsByYear W30763293542023 @default.